Dianthus Therapeutics (NASDAQ:DNTH) Trading Up 12% – Here’s What Happened

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price shot up 12% on Tuesday . The company traded as high as $42.71 and last traded at $43.8280. 578,700 shares were traded during trading, a decline of 13% from the average session volume of 662,264 shares. The stock had previously closed at $39.12.

Analyst Upgrades and Downgrades

DNTH has been the topic of a number of recent research reports. Wedbush reissued an “outperform” rating and issued a $46.00 target price on shares of Dianthus Therapeutics in a report on Monday, December 22nd. HC Wainwright increased their price target on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Truist Financial boosted their price objective on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $64.43.

Dianthus Therapeutics Trading Up 14.7%

The stock has a market cap of $1.92 billion, a P/E ratio of -12.89 and a beta of 1.55. The stock’s 50-day moving average is $40.79 and its 200-day moving average is $32.33.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. On average, equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction on Friday, November 14th. The stock was sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the transaction, the executive vice president owned 4,000 shares in the company, valued at $152,560. The trade was a 96.46% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 216,538 shares of company stock valued at $8,283,175 in the last quarter. Insiders own 16.56% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC acquired a new stake in Dianthus Therapeutics during the 4th quarter valued at $765,000. JPMorgan Chase & Co. grew its holdings in shares of Dianthus Therapeutics by 626.4% during the third quarter. JPMorgan Chase & Co. now owns 68,124 shares of the company’s stock valued at $2,681,000 after buying an additional 58,746 shares in the last quarter. TCG Crossover Management LLC grew its holdings in shares of Dianthus Therapeutics by 11.7% during the third quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock valued at $65,975,000 after buying an additional 175,000 shares in the last quarter. Vivo Capital LLC acquired a new position in Dianthus Therapeutics during the third quarter valued at $13,930,000. Finally, Polar Capital Holdings Plc purchased a new stake in Dianthus Therapeutics in the 3rd quarter worth about $29,434,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.